Literature DB >> 8080486

Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat.

P Widler1, H U Fisch, P Schoch, A Zimmermann, T E Schläpfer, J Reichen.   

Abstract

Increased levels of natural benzodiazepine receptor agonists, produced in the body (endogenous) or ingested with food (exogenous) have been proposed as one of the factors causing hepatic encephalopathy in both experimental animals and human subjects. However, the divergent response of hepatic encephalopathy to benzodiazepine antagonists sheds doubt on this attractive hypothesis. Acute liver failure was induced in male Sprague-Dawley rats (n = 17) with intraperitoneal thioacetamide (600 mg/kg/day for 3 days) while 14 control rats received vehicle only. Acute liver failure developed in all treated rats (AST: 1,898 +/- 1,359 IU/L vs. controls, 45 +/- 5 IU/L, p < 0.005; bilirubin: 36 +/- 27 mumol/L vs. controls, 1.5 +/- 0.5 mumol/L, p < 0.005; centrizonal necrosis) and grade 3 or 4 hepatic encephalopathy (neurologic assessment and activity monitoring). However, benzodiazepine receptor ligand activity, measured in the supernatant of whole-brain homogenates with a [3H]flumazenil binding competition assay, was clearly increased in only 1 of 17 rats with acute liver failure compared with controls (52.7 +/- 34.1 vs. 44.3 +/- 18.9 ng diazepam equivalents/gm; NS). To evaluate whether the reported increase in benzodiazepine receptor ligand activity could be due to prolonged residence of exogenous benzodiazepine-like substances, additional rats with acute liver failure and controls were treated with diazepam (five doses of 0.5 mg/kg at 12-hr intervals by gavage). Benzodiazepine receptor ligand activity was greater in animals with acute liver failure than in controls (223 +/- 65 vs. 103 +/- 23 ng diazepam equivalents/gm; p < 0.002) 1 to 3 hr after the last diazepam dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8080486

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

Review 1.  Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure.

Authors:  Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2014-07-09

Review 2.  Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

3.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

4.  Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.

Authors:  H P Meyer; D A Legemate; W van den Brom; J Rothuizen
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

5.  Plasma concentrations of endogenous benzodiazepine-receptor ligands in patients with hepatic encephalopathy: a comparative study.

Authors:  C A Hernández-Avila; W J Shoemaker; H A Ortega-Soto
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.